Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

August 31, 2017

Primary Completion Date

May 8, 2019

Study Completion Date

January 11, 2021

Conditions
Waldenström's Macroglobulinemia (WM)
Interventions
DRUG

Zanubrutinib

Oral administration using 80 mg capsules

Trial Locations (10)

100021

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

100730

Peking Union Medical College Hospital, Beijing

200025

Rui Jin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai

210029

Jiangsu Province Hospital, Nanjing

215006

The First Affiliated Hospital of Soochow University Branch Shizi, Suzhou

310003

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

430030

Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan

450000

Henan Cancer Hospital, Zhengzhou

510080

Guangdong Provincial Peoples Hospital, Guangzhou

610041

West China Hospital, Sichuan University, Chengdu

Sponsors

Lead Sponsor

All Listed Sponsors
lead

BeiGene

INDUSTRY